Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

BMC Cancer

Table 1 Patient characteristics in the gefitinib and erlotinib groups

Characteristics	Gefitinib (n = 232)	Erlotinib (n = 86)	p value
Median age (Range)	67 (24–90)	66 (34–90)	0.36
< 70	139	57
≥ 70	93	29
Gender			0.90
Male	105	38
Female	127	48
Histology			0.32
Adenocarcinoma	223	80
Squamous cell carcinoma	8	5
Other	1	1
Smoking status			0.38
Ever smoker	130	43
Never smoker	102	43
ECOG performance status			0.001
0	30	11
1	143	68
≥ 2	59	7
EGFR mutation status			< 0.001
Positive	91	53
Negative	4	22
Unknown	137	11
Stage			0.75
≤ IIIB	48	16
IV	184	70
CYP2D6 activity			0.42
functional	156	64
reduced	50	16
unknown	26	6
HBs antigen			1.00
Positive	2	0
Negative	211	85
Unknown	2	1
HCV antibody			0.10
Positive	15	5
Negative	200	80
Unknown	17	1
Pretreatment LFT			0.42
normal	155	62
abnormal	77	24

*Fisher’s exact test were applied to compare patient characteristics.
ECOG, Eastern Cooperative Oncology Group; EGFR, Epidermal Growth Factor Receptor; HCV, hepatitis C virus; HBs, hepatitis B surface; LFT, liver function test; CYP2D6, cytochrome P450 2D6.

ISSN: 1471-2407